Oruka Therapeutics (ORKA) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Alpha Teknova (TKNO) over the past year, gaining 286.5% versus a gain of 66.2%. Over five years, ORKA leads with a +137.5% price change compared with -62.3% for TKNO. Oruka Therapeutics is the larger company by market cap ($5.26 billion vs $467.6 million), about 11.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORKA | TKNO |
|---|---|---|
| Share price | $79.50 | $8.71 |
| Market cap | $5.26B | $467.62M |
| 1-day change | -0.85% | -0.46% |
| YTD return | +162.29% | +129.21% |
| 1-year return | +286.49% | +66.22% |
| 5-year return | +137.46% | -62.29% |
| EPS (TTM) | $-1.94 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-105.43M | — |
| 52-week high | $115.52 | $9.48 |
| 52-week low | $20.25 | $1.91 |
| Distance from 52-week high | -31.18% | -8.12% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +94.97% | — |
| Average volume | 889.85K | 232.52K |
| Shares outstanding | 66.21M | 53.69M |
| Employees | 68 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Oruka Therapeutics is about 11.3 times larger than Alpha Teknova by market value ($5.26B vs $467.62M).
- ORKA has outperformed TKNO by 220.3 percentage points over the past year.
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
ORKA vs TKNO FAQ
Which is bigger, Oruka Therapeutics or Alpha Teknova?
Oruka Therapeutics (ORKA) is larger, with a market capitalization of $5.26B compared with $467.62M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, ORKA or TKNO?
ORKA returned +286.49% over the past 12 months, compared with +66.22% for TKNO (price return, excluding dividends). Past performance does not predict future results.
Are Oruka Therapeutics and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.